

FORM PTO-1449

U. S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK
OFFICE

ATTY. DOCKET NO.

SERIAL NO.

U 013589-7

09/890,989

APPLICANT

Peter David DAVIS

FILING DATE

GROUP

December 14,

1614

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIALS	REFERENCE DESIGNATION	DOCUMENT NUMBER	DATE	NAME	FILING DATE IF APPROPRIATE
	AA				
	AB				
	AC				
	AD				
	AE				
	AF				
	AG				
	AH				
	AI				
	AJ				
	AK				

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AL					
	AM					
	AN					
	AO					
	AP					

OTHER ART (Including Author, Title, Date, Pertinent Dates, Etc.)

my	AR	Annex A - Combretastatin A-4 Phosphate as a Tumor Vascular-Targeting Agent: Early Effects in Tumors and Normal Tissues: Tozer, Prise, Wilson, Locke, Vojnovic, Stratford, Dennis, Chaplin: Cancer Research 59, 1626-1634, April 1, 1999
↓	AS	Annex B - Enhancement of Vascular Targeting by Inhibitors of Nitric Oxide Synthase: Davis, Tozer, Naylor, Thomson, Lewis, Hill: Int. J. Radiation Oncology Biol. Phys. Vol. 54, No. 5 pp. 1532-1536, 2002
↓	AT	Annex C - Effect of the tumor vascular damaging agent, ZD6126 on the radioresponse of U97 glioblastoma: Wachsberger, Burd, Marrero, Daskalakis, Ryan, McCue, Dicker:

EXAMINER

mish 7

DATE CONSIDERED

3-20-06

EXAMINER:

Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.